- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Acute visual loss after ipilimumab treatment for metastatic melanoma ; volume:4 ; number:1 ; day:18 ; month:10 ; year:2016 ; pages:1-7 ; date:12.2016
Journal for ImmunoTherapy of Cancer ; 4, Heft 1 (18.10.2016), 1-7, 12.2016
- Creator
-
Wilson, Melissa A.
- Contributor
-
Guld, Kelly
Galetta, Steven
Walsh, Ryan D.
Kharlip, Julia
Tamhankar, Madhura
McGettigan, Suzanne
Schuchter, Lynn M.
Fecher, Leslie A.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-016-0170-9
- URN
-
urn:nbn:de:1111-20161112684
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wilson, Melissa A.
- Guld, Kelly
- Galetta, Steven
- Walsh, Ryan D.
- Kharlip, Julia
- Tamhankar, Madhura
- McGettigan, Suzanne
- Schuchter, Lynn M.
- Fecher, Leslie A.
- SpringerLink (Online service)
Other Objects (12)
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
Ipilimumab in patients with melanoma and autoimmune disease
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
Ipilimumab in patients with melanoma and autoimmune disease
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
Ipilimumab in patients with melanoma and autoimmune disease
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma